네온크 테크놀로지스, 교모세포종 임상 2a상 긍정적 결과에 주가 급등
생명공학 기업 네온크 테크놀로지스(NASDAQ: NTHI)가 재발성 교모세포종 치료제 후보물질 'NEO100'의 임상 2a상에서 긍정적인 탑라인 데이터를 발표한 후 주가가 11.7% 급등했다. 회사는 주요 평가지표를 충족했으며, 미국 식품의약국(FDA)과 허가 등록 경로에 대해 논의할 계획이다.
Nasdaq 100
IndicesLive Nasdaq 100 price, interactive chart, latest news, and the top brokers to trade it — all in one place.
Live Nasdaq 100 Chart
Technical Summary
Top Brokers to Trade Nasdaq 100
These top-rated brokers on TrustFinance offer Nasdaq 100 trading with competitive spreads and strong regulation.
IC MarketsScore 88ASIC, CySEC, FSATrade →XMScore 84Cyprus Securities and Exchange Commission, Financial Sector Conduct Authority, Dubai Financial Services Authority, The Seychelles Financial Services AuthorityTrade →ExnessScore 68Cyprus Securities and Exchange Commission, Financial Conduct Authority, Financial Services Authority, Central Bank of Curaçao and Sint Maarten, British Virgin Islands Financial Services Commission, Financial Sector Conduct Authority, Capital Markets Authority, Mauritius' Financial Services CommissionTrade →PepperstoneScore 39Trade →
Broker ratings are based on independent reviews on TrustFinance.com. Trade responsibly. CFDs carry risk.
Latest Nasdaq 100 News